.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Fuji
Cantor Fitzgerald
Express Scripts
Merck
UBS
Deloitte
Covington
AstraZeneca
Cerilliant

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,545,644

« Back to Dashboard

Which drugs does patent 5,545,644 protect, and when does it expire?


Patent 5,545,644 protects RELPAX and is included in one NDA. There has been one Paragraph IV challenge on Relpax.

This patent has ninety-four patent family members in thirty-six countries.

Summary for Patent: 5,545,644

Title: Indole derivatives
Abstract:Compounds of the formula ##STR1## wherein n is 0, 1, or 2; X is hydrogen, chlorine, bromine or iodine; R.sub.1 is hydrogen; R.sub.3 is selected from hydrogen and C.sub.1 to C.sub.6 linear or branched alkyl; and R.sub.2 is as defined in the specification and the pharmaceutically acceptable salts thereof are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators. A process for forming indoles by transition metal catalyzed cyclization of a dihalogenated intermediate is also disclosed.
Inventor(s): Macor; John E. (New York, NY), Wythes; Martin J. (New York, NY)
Assignee: Pfizer Inc. (New York, NY)
Application Number:08/466,644
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002RXYesNo5,545,644► SubscribeYY TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002RXYesYes5,545,644► SubscribeYY TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,545,644

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,607,951 Indole derivatives► Subscribe
5,559,129 Indole derivatives► Subscribe
5,578,612 Indole derivatives► Subscribe
5,559,246 Indole derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,545,644

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)486► Subscribe
African Regional IP Organization (ARIPO)9400633► Subscribe
Austria157361► Subscribe
Austria222492► Subscribe
Australia6436094► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Queensland Health
Deloitte
US Department of Justice
Citi
Chinese Patent Office
Fish and Richardson
Mallinckrodt
Merck
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot